1. Lymphadenopathy in COVID-19 Vaccine Recipients: Diagnostic Dilemma in Oncology Patients
- Author
-
Evidio Domingo-Musibay, Can Özütemiz, Daniel Steinberger, Luke A. Krystosek, Jutta M. Ellermann, Anil Chauhan, and An L Church
- Subjects
Adult ,Male ,medicine.medical_specialty ,COVID-19 Vaccines ,Lymph node biopsy ,Lymphadenopathy ,Physical examination ,Breast Neoplasms ,030218 nuclear medicine & medical imaging ,Metastasis ,Diagnosis, Differential ,03 medical and health sciences ,0302 clinical medicine ,Positron Emission Tomography Computed Tomography ,Biopsy ,medicine ,Axillary Lymphadenopathy ,Humans ,Radiology, Nuclear Medicine and imaging ,Case Series ,Melanoma ,medicine.diagnostic_test ,business.industry ,SARS-CoV-2 ,COVID-19 ,Middle Aged ,medicine.disease ,Liposarcoma, Myxoid ,Vaccination ,030220 oncology & carcinogenesis ,Lymphatic Metastasis ,Female ,Radiology ,Lymph Nodes ,Differential diagnosis ,business - Abstract
Five cases of axillary lymphadenopathy are presented, which occurred after COVID-19 vaccination and mimicked metastasis in a vulnerable oncologic patient group. Initial radiologic diagnosis raised concerns for metastasis. However, further investigation revealed that patients received COVID-19 vaccinations in the ipsilateral arm prior to imaging. In two cases, lymph node biopsy results confirmed vaccination-related reactive lymphadenopathy. Ipsilateral axillary swelling or lymphadenopathy was reported based on symptoms and physical examination in COVID-19 vaccine trials. Knowledge of the potential for COVID-19 vaccine-related ipsilateral adenopathy is necessary to avoid unnecessary biopsy and change in therapy. © RSNA, 2021.
- Published
- 2021